Wholecoiner inflows to Binance have reached cycle lows, according to on-chain analytics firm CryptoQuant, indicating a potential decrease in sell pressure for Bitcoin (BTC). This metric, tracking addresses holding at least 1 BTC, suggests shifting market dynamics that could support price stabilization or upward momentum.Wholecoiner inflows to Binance have reached cycle lows, according to on-chain analytics firm CryptoQuant, indicating a potential decrease in sell pressure for Bitcoin (BTC). This metric, tracking addresses holding at least 1 BTC, suggests shifting market dynamics that could support price stabilization or upward momentum.

Wholecoiner Inflows to Binance Hit Cycle Lows, Signaling Reduced Sell Pressure

2025/12/15 20:49
2 min read
For feedback or concerns regarding this content, please contact us at crypto.news@mexc.com

Keywords: Wholecoiner Binance inflows, CryptoQuant Bitcoin analysis, reduced Bitcoin sell pressure, Bitcoin cycle lows, crypto market signals

Wholecoiner inflows to Binance have reached cycle lows, according to on-chain analytics firm CryptoQuant, indicating a potential decrease in sell pressure for Bitcoin (BTC). This metric, tracking addresses holding at least 1 BTC, suggests shifting market dynamics that could support price stabilization or upward momentum.

CryptoQuant's Insights on Wholecoiner Inflows
CryptoQuant's data shows wholecoiner inflows—transfers of 1+ BTC to Binance—dropping to levels not seen since the last market cycle low in 2022. Typically, high inflows signal selling intent, as holders move coins to exchanges for liquidation. The current low (around 500 BTC daily) implies reduced dumping, allowing accumulation by long-term holders.

This aligns with Bitcoin's consolidation around $60,000, where on-chain metrics like realized price and holder behavior point to a bottoming phase. CryptoQuant analyst Julio Moreno noted, "Low wholecoiner inflows often precede rallies, as sell pressure eases."

What Are Wholecoiners and Why They Matter
Wholecoiners are addresses with at least one full BTC, representing committed investors rather than fractional holders. Their inflows to exchanges like Binance are a key sell-pressure gauge. Cycle lows in this metric have historically coincided with market bottoms, such as post-2018 crash or 2022 bear market.

The decline could stem from holders awaiting higher prices or institutional shifts via ETFs, reducing the need for exchange sales.

Implications for Bitcoin Market
Reduced sell pressure is bullish, potentially paving the way for BTC to test $70,000 resistance. Combined with ETF inflows and halving effects, it supports a recovery narrative. However, external factors like macroeconomics could override this.

Market reactions saw BTC up 1.5% post-report, reflecting optimism. "This signals the end of capitulation," said trader Peter Brandt.

Outlook and Investor Advice
If inflows remain low, expect increased buying interest. Monitor CryptoQuant for updates on Bitcoin cycle lows and reduced sell pressure. While positive, crypto volatility persists—use risk management and diversify.

Disclaimer: The articles published on this page are written by independent contributors and do not necessarily reflect the official views of MEXC. All content is intended for informational and educational purposes only and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC. Cryptocurrency markets are highly volatile — please conduct your own research and consult a licensed financial advisor before making any investment decisions.

You May Also Like

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Key Takeaways Vitalik Buterin wants Ethereum apps built to survive without developers, corporate servers, or trusted third parties Two major […] The post Vitalik
Share
Coindoo2026/03/07 15:49
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26
Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

The post Short-term profit-taking pushes Bitcoin back below key $70K level – What next? appeared on BitcoinEthereumNews.com. Bitcoin [BTC] rallied as high as $74
Share
BitcoinEthereumNews2026/03/07 16:09